Dachaigh › Aillse a' bhroilleach › Nevada
Sgrùdaidhean clionaigeach Aillse a' bhroilleach ann an Nevada
Tha 19 sgrùdaidhean airson Aillse a' bhroilleach a’ lorg phàirtichean aig làraichean ann an Nevada.
Bailtean ann an Nevada
Teacsa sgrùdaidh oifigeil (Beurla)
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
- Renown Health Medical Oncology, Reno
A’ fastadhÌre 3
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 5 Dàmh 2026 · NCT06982521Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
- Cancer Care Specialists, Reno
A’ fastadhÌre 3
Aoisean 18 gu 100 · Gach gnè · Air ùrachadh 2 Dàmh 2026 · NCT05827081Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Carson Tahoe Regional Medical Center, Carson City
- Comprehensive Cancer Centers of Nevada - Henderson, Henderson
- Comprehensive Cancer Centers of Nevada-Horizon Ridge, Henderson
- agus 25 a bharrachd
A’ fastadhSgrùdadh amharcFàilte do shaor-thoilich fhallain
Aoisean 40 gu 75 · Gach gnè · Air ùrachadh 2 Dàmh 2026 · NCT05334069A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer
- Cancer Care Specialists, Reno
A’ fastadhÌre 2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 1 Dàmh 2026 · NCT06369285A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
- Optum Care Cancer Center ( Site 0050), Las Vegas
- Renown Regional Medical Center ( Site 0041), Reno
A’ fastadhÌre 3
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 25 Sult 2026 · NCT06966700A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
- Renown Regional Medical Center, Reno
A’ fastadhÌre 1/2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 10 Sult 2026 · NCT03424005A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer
- Research Site, Reno
A’ fastadhÌre 3
Aoisean 18 gu 130 · Gach gnè · Air ùrachadh 8 Sult 2026 · NCT07647328Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies
- Cancer Care Specialist of Reno, Reno
A’ fastadhSgrùdadh amharc
Aoisean 18 gu 99 · Gach gnè · Air ùrachadh 3 Sult 2026 · NCT07211178Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
- Carson Tahoe Regional Medical Center, Carson City
- Comprehensive Cancer Centers of Nevada - Henderson, Henderson
- Comprehensive Cancer Centers of Nevada-Horizon Ridge, Henderson
- agus 25 a bharrachd
A’ fastadhÌre 3
Aoisean 18 gu 60 · Banairean · Air ùrachadh 2 Sult 2026 · NCT05879926A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
- Comprehensive Cancer Centers of Nevada, Las Vegas
A’ fastadhÌre 1
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 28 Lùna 2026 · NCT07029399A Pivotal Phase II Clinical Trial of Utidelone Injection Plus Capecitabine in HER2-negative Breast Cancer Patients With Brain Metastases
- Comprehensive Cancer Centers of Nevada, Las Vegas
A’ fastadhÌre 2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 21 Lùna 2026 · NCT06764940Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects
- Comprehensive Cancer Centers of Nevada, Henderson
A’ fastadhÌre 3
Aoisean 18 gu 100 · Gach gnè · Air ùrachadh 6 Lùna 2026 · NCT05232916A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
- Comprehensive Cancer Centers of Nevada, Las Vegas
A’ fastadhÌre 1/2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 29 Ògmh 2026 · NCT05377996Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
- Renown Regional Medical Centre, Reno
- Cancer Care Specialists, Reno
A’ fastadhÌre 3
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 22 Ògmh 2026 · NCT05696626A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
- Comprehensive Cancer Centers of Nevada, Henderson
- Comprehensive Cancer Centers of Nevada, Henderson
- Comprehensive Cancer Centers of Nevada, Las Vegas
- agus 3 a bharrachd
A’ fastadhÌre 3
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 6 Cèit 2026 · NCT07062965De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
- OptumCare Cancer Care at Seven Hills, Henderson
- OptumCare Cancer Care at Charleston, Las Vegas
- Radiation Oncology Centers of Nevada Central, Las Vegas
- agus 8 a bharrachd
A’ fastadhÌre 3
Aoisean 50 gu 70 · Gach gnè · Air ùrachadh 23 Gibl 2026 · NCT04852887A Study to Evaluate the Safety and Tolerability of TOS-358 in Women With HR+ HER2- Breast Cancer
- Comprehensive Cancer Centers of Nevada, Las Vegas
A’ fastadhÌre 1
Aoisean 18 agus nas sine · Banairean · Air ùrachadh 22 Gibl 2026 · NCT05683418Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
- OptumCare Cancer Care at Seven Hills, Henderson
- OptumCare Cancer Care at Charleston, Las Vegas
A’ fastadhSgrùdadh amharc
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 17 Màrt 2026 · NCT06418204First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer
- Renown Regional Medical Center, Reno
A’ fastadhÌre 1
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 22 Sult 2025 · NCT05216432Bho ClinicalTrials.gov, dàta air a thogail 6 Dàmh 2026. Bidh gach sgrùdadh a’ suidheachadh a chuidi fhèin; bidh an sgioba sgrùdaidh a’ co-dhùnadh cò as urrainn pàirt a ghabhail.